TITLE

Antiretroviral Therapy: Optimal Sequencing of Therapy to Avoid Resistance

AUTHOR(S)
Martinez-Cajas, Jorge L.; Wainberg, Mark A.
PUB. DATE
January 2008
SOURCE
Drugs;2008, Vol. 68 Issue 1, p43
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In the second decade of highly active antiretroviral therapy, drug regimens offer more potent, less toxic and more durable choices. However, strategies addressing convenient sequential use of active antiretroviral combinations are rarely presented in the literature. Studies have seldom directly addressed this issue, despite it being a matter of daily use in clinical practice. This is, in part, because of the complexity of HIV-1 resistance information as well as the complexity of designing these types of studies. Nevertheless, several principles can effectively assist the planning of antiretroviral drug sequencing. The introduction of tenofovir disoproxil fumarate, abacavir and emtricitabine into current nucleoside backbone options, with each of them selecting for an individual pattern of resistance mutations, now permits sequencing in the context of previously popular thymidine analogues (zidovudine and stavudine). Similarly, newer ritonavirboosted protease inhibitors could potentially be sequenced in a manner that uses the least cross-resistance prone protease inhibitor at the start of therapy, while leaving the most cross-resistance prone drugs for later, as long as there is rationale to employ such a compound because of its utility against commonly observed drug-resistant forms of HIV-1.
ACCESSION #
28406055

 

Related Articles

  • Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel. Yeni, Patrick G.; Hammer, Scott M.; Hirsch, Martin S.; Saag, Michael S.; Schechter, Mauro; Carpenter, Charles C. J.; Fischl, Margaret A.; Gatell, Jose M.; Gazzard, Brian G.; Jacobsen, Donna M.; Katzenstein, David A.; Montaner, Julio S. G.; Richman, Douglas D.; Schooley, Robert T.; Thompson, Melanie A.; Vella, Stefano; Volberding, Paul A. // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p251 

    Context Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection. Objective To update recommendations for physicians who provide...

  • Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A Randomized Trial. Saag, Michael S.; Cahn, Pedro; Raffi, François; Wolff, Marcelo; Pearce, Daniel; Molina, Jean-Michel; Powderly, William; Shaw, Audrey L.; Mondou, Elsa; Hinkle, John; Borroto-Esoda, Katyna; Quinn, Joseph B.; Barry, David W.; Rousseau, Franck // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p180 

    Context Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV). Objective To assess the efficacy and safety of emtricitabine as compared with stavudine when used with a background regimen of didanosine...

  • Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial. Gallant, Joel E.; Staszewski, Schlomo; Pozniak, Anton L.; DeJesus, Edwin; Suleiman, Jamal M. A. H.; Miller, Michael D.; Coakley, Dion F.; Lu, Biao; Toole, John J.; Cheng, Andrew K. // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p191 

    Context Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor. Objective To evaluate the efficacy and safety of tenofovir DF compared with stavudine in antiretroviral-naive patients. Design, Setting, and Participants A prospective, randomized,...

  • Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). Torti, Carlo; Raffetti, Elena; Donato, Francesco; Castelli, Francesco; Maggiolo, Franco; Angarano, Gioacchino; Mazzotta, Francesco; Gori, Andrea; Sighinolfi, Laura; Pan, Angelo; Cauda, Roberto; Scalzini, Alfredo; Quiros-Roldan, Eugenia; Nasta, Paola; Gregis, Giampietro; Benatti, Simone; Digiambenedetto, Simona; Ladisa, Nicoletta; Giralda, Mariarosaria; Saracino, Annalisa // International Journal of Epidemiology;Apr2017, Vol. 46 Issue 2, p1 

    No abstract available.

  • Treatment of HIV/AIDS: Do the Dilemmas Only Increase? Sande, Merle A.; Ronald, Allan // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p266 

    Presents an editorial on HIV/AIDS treatment and mentions articles in this issue of "JAMA". Guidelines set by the International AIDS Society-USA (IAS-USA) for HIV care reported in this issue; View that clinical trials using highly active antiretroviral therapy (HAART) should be redirected to...

  • Clinical Trials in Sub-Saharan Africa and Established Standards of Care: A Systematic Review of HIV, Tuberculosis, and Malaria Trials. Kent, David M.; Mwamburi, D. Mkaya; Bennish, Michael L.; Kupelnick, Bruce; Ioannidis, John P. A. // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p237 

    Context The minimum standard of care required for participants in clinical trials conducted in resource-poor settings is a matter of controversy; international documents offer contradictory guidance. Objective To determine whether recently published trials conducted in sub-Saharan Africa met...

  • Moving Beyond Biomedicalization in the HIV Response: Implications for Community Involvement and Community Leadership Among Men Who Have Sex with Men and Transgender People. Aggleton, Peter; Parker, Richard // American Journal of Public Health;Aug2015, Vol. 105 Issue 8, p1552 

    The article discusses challenges confronting efforts to address and respond to the HIV/AIDS epidemic. Topics include an increase in new HIV infections among men who have sex with men (MSM), transgender people, and other socially excluded groups, the encouragement of discrimination and hostility...

  • Strategies for Preventing Mucosal Cell-Associated HIV Transmission. Whaley, Kevin J.; Mayer, Kenneth H. // Journal of Infectious Diseases;Dec2014, Vol. 210 Issue suppl_3, pS674 

    Human immunodeficiency virus (HIV) may be transmitted through either cell-free virions or leukocytes harboring intracellular HIV in bodily fluids. In recent years, the early initiation of combination antiretroviral therapy leading to virological suppression has resulted in decreased HIV...

  • Assessment of hematological adverse drug reactions to antiretroviral therapy in HIV positive patients at Kasturba Hospital Manipal. Pulagam, Poornima; Rajesh, Radhakrishnan; Vidyasagar, Sudha; Varma, Danturulu Muralidhar // BMC Infectious Diseases;2012 Supplement, Vol. 12 Issue Supplment 1, p1 

    The article presents a study on the hematological adverse drug reactions (ADRs) associated with highly active antiretroviral therapy in HIV positive patients in India. The authors investigate the casuality, incidence rate and severity pattern of hematological ADRs among HIV patients. The study...

  • Factors associated with adherence to antiretroviral therapy in HIV-infected patients in Kathmandu District, Nepal. Shigdel, Rajesh; Klouman, Elise; Bhandari, Anita; Ahmed, Luai A. // HIV/AIDS - Research & Palliative Care;2014, Vol. 6, p109 

    Purpose: There are a high number of HIV-infected patients receiving antiretroviral therapy (ART) in the Kathmandu District of Nepal, but information on adherence and factors influencing it are scarce in this population. The present study aimed to estimate ART adherence among HIV-infected...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics